Tilbroquinol

DB13222ApprovedSmall molecule

Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit... In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.

Formula / weight: C₁₀H₈BrNO · 238.084 g/mol (avg)

Resolves to

Compound

UNIIP6SB125NHACAS7175-09-9ChEMBLCHEMBL1788385ChEBI134965

Clinical / RWD

RxNorm166718ATCP01AA05ATCP01AA30

Structure

InChIKeyJMOVFFLYGIQXMM-UHFFFAOYSA-NSMILESCC1=C2C=CC=NC2=C(O)C(Br)=C1

What you can answer from here — as of February 21, 2021

558Drug interactionsStructured to mechanism, not free text

2ATC codesIncluding every combination product, plus 8 drug categories

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Tilbroquinol, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account